{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T14:24:41Z","timestamp":1709821481135},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00108-017-0262-8","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T08:50:37Z","timestamp":1497862237000},"page":"666-674","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ma\u00dfgeschneiderte Therapie der Virushepatitis der Gegenwart und Zukunft"],"prefix":"10.1007","volume":"58","author":[{"given":"R.","family":"Bartenschlager","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"262_CR1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg M, Protzer U, Petersen J et\u00a0al (2011) Prophylaxis, diagnosis and therapy of hepatitis B virus infection \u2013 the German guideline. Z\u00a0Gastroenterol 49:871\u2013930","journal-title":"Z Gastroenterol"},{"key":"262_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HL, Chan HL (2017) The role of quantitative hepatitis B surface antigen revisited. J\u00a0Hepatol 66:398\u2013411","journal-title":"J Hepatol"},{"key":"262_CR3","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","volume":"63","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Cholongitas E et\u00a0al (2016) Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 63:1481\u20131492","journal-title":"Hepatology"},{"key":"262_CR4","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","volume":"214","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen C, Rinker F, Maasoumy B et al (2016) Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HbeAg-negative chronic hepatitis B. J\u00a0Infect Dis 214:1492\u20131497","journal-title":"J Infect Dis"},{"key":"262_CR5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP3014","volume":"21","author":"M Cornberg","year":"2016","unstructured":"Cornberg M, Wiegand SB (2016) ImPortance of IP-10 in hepatitis B. Antivir Ther (Lond) 21:93\u201396","journal-title":"Antivir Ther (Lond)"},{"key":"262_CR6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","volume":"61","author":"F B\u00f6mmel van","year":"2015","unstructured":"van B\u00f6mmel F, Bartens A, Mysickova A et\u00a0al (2015) Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61:66\u201376","journal-title":"Hepatology"},{"key":"262_CR7","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","volume":"21","author":"B Maasoumy","year":"2015","unstructured":"Maasoumy B, Wiegand SB, Jaroszewicz J et al (2015) Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a\u00a0large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 21:606.e1\u2013606.e10","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"262_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","volume":"26","author":"J Petersen","year":"2008","unstructured":"Petersen J, Dandri M, Mier W et\u00a0al (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26(3):335\u2013341","journal-title":"Nat Biotechnol"},{"key":"262_CR9","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G et\u00a0al (2012) Sodium taurocholate cotransporting polypeptide is a\u00a0functional receptor for human hepatitis B and D virus. Elife 1:e00049","journal-title":"Elife"},{"key":"262_CR10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov P, Alexandrov A, Voronkova N et\u00a0al (2016) Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a\u00a0phase Ib\/IIa study. J\u00a0Hepatol 65:490\u2013498","journal-title":"J Hepatol"},{"key":"262_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","volume":"147","author":"S Urban","year":"2014","unstructured":"Urban S, Bartenschlager R, Kubitz R, Zoulim F (2014) Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147:48\u201364","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"262_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/liv.13307","volume":"37","author":"B Testoni","year":"2017","unstructured":"Testoni B, Durantel D, Zoulim F (2017) Novel targets for hepatitis B virus therapy. Liver Int 37(Suppl 1):33\u201339","journal-title":"Liver Int"},{"key":"262_CR13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","volume":"531","author":"A Decorsi\u00e8re","year":"2016","unstructured":"Decorsi\u00e8re A, Mueller H, van Breugel PC et\u00a0al (2016) Hepatitis B virus X protein identifies the Smc5\/6 complex as a\u00a0host restriction factor. Nature 531:386\u2013389","journal-title":"Nature"},{"key":"262_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.049","author":"Y Lobaina","year":"2017","unstructured":"Lobaina Y, Michel ML (2017) Chronic hepatitis B: immunological profile and current therapeutic vaccines in clinical trials. Vaccine. doi: 10.1016\/j.vaccine.2017.03.049","journal-title":"Vaccine"},{"key":"262_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","volume":"7","author":"H Wedemeyer","year":"2010","unstructured":"Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31\u201340","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"262_CR16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coviro.2016.10.002","volume":"20","author":"A Wranke","year":"2016","unstructured":"Wranke A, Wedemeyer H (2016) Antiviral therapy of hepatitis delta virus infection \u2013 progress and challenges towards cure. Curr Opin Virol 20:112\u2013118","journal-title":"Curr Opin Virol"},{"issue":"11","key":"262_CR17","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/jvh.12251","volume":"21","author":"B Calle Serrano","year":"2014","unstructured":"Calle Serrano B, Grosshennig A, Homs M et al (2014) Development and evaluation of a\u00a0baseline-event-anticipation score for hepatitis delta. J\u00a0Viral Hepat 21(11):e154\u2013e163","journal-title":"J Viral Hepat"},{"key":"262_CR18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Dahari H et al (2015) Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a\u00a0proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 15:1167\u20131174","journal-title":"Lancet Infect Dis"},{"key":"262_CR19","first-page":"121A","volume":"64","author":"H Wedemeyer","year":"2016","unstructured":"Wedemeyer H, Port K, Deterding K et al (2016) A phase 2 study of titrating-dose Lonafarnib plus Ritonavir in patients with chronic hepatitis D: interim results from the Lonafarnib with Ritonavir in HDV-4 (LOWR HDV-4) study. Hepatology 64:121A","journal-title":"Hepatology"},{"key":"262_CR20","first-page":"910A","volume":"64","author":"C Yurdaydin","year":"2016","unstructured":"Yurdaydin C, Idilman R, Kalkan C et al (2016) Exploring optimal dosing of Lonafarnib with Ritonavir for the treatment of chronic delta hepatitis \u2013 interim results from the Lowr HDV-2 study. Hepatology 64:910A","journal-title":"Hepatology"},{"key":"262_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"EASL","year":"2017","unstructured":"EASL (2017) EASL recommendations on treatment of hepatitis C 2016. J\u00a0Hepatol 66:153\u2013194","journal-title":"J Hepatol"},{"key":"262_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-0028-1110008","volume":"48","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Berg T, Ross RS et\u00a0al (2010) Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z\u00a0Gastroenterol 48:289\u2013351","journal-title":"Z Gastroenterol"},{"key":"262_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","volume":"1","author":"G Lau","year":"2016","unstructured":"Lau G, Benhamou Y, Chen G et al (2016) Efficacy and safety of 3\u2011week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a\u00a0phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 1:97\u2013104","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"262_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30029","author":"M Cornberg","year":"2016","unstructured":"Cornberg M, Manns MP (2016) Hepatitis C: individualised medicine versus one pill fits all. Lancet Gastroenterol Hepatol. doi: 10.1016\/S2468-1253(16)30029","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"262_CR25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jvh.12249","volume":"21","author":"H Wedemeyer","year":"2014","unstructured":"Wedemeyer H, Duberg AS, Buti M et\u00a0al (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J\u00a0Viral Hepat 21(Suppl 1):60\u201389","journal-title":"J Viral Hepat"},{"key":"262_CR26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12916-015-0440-2","volume":"13","author":"N Scott","year":"2015","unstructured":"Scott N, McBryde E, Vickerman P et al (2015) The role of a\u00a0hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 13:198","journal-title":"BMC Med"},{"key":"262_CR27","doi-asserted-by":"crossref","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 61(1 Suppl):45\u201357","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"262_CR28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.aad1302","volume":"349","author":"AL Cox","year":"2015","unstructured":"Cox AL (2015) MEDICINE. Global control of hepatitis C virus. Science 349:790\u2013791","journal-title":"Science"},{"key":"262_CR29","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021, towards ending viral hepatitis","author":"WHO","year":"2016","unstructured":"WHO (2016) Global health sector strategy on viral hepatitis 2016\u20132021, towards ending viral hepatitis. http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/ . Zugegriffen: 24.5.2017"},{"key":"262_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.025","author":"QL Zeng","year":"2017","unstructured":"Zeng QL, Xu GH, Zhang JY et al (2017) Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J\u00a0Hepatol. doi: 10.1016\/j.jhep.2017.01.025","journal-title":"J Hepatol"},{"key":"262_CR31","doi-asserted-by":"crossref","first-page":"282ra49","DOI":"10.1126\/scitranslmed.3010286","volume":"7","author":"S He","year":"2015","unstructured":"He S, Lin B, Chu V et\u00a0al (2015) Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med 7:282ra49","journal-title":"Sci Transl Med"},{"key":"262_CR32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.28111","volume":"63","author":"PM Perin","year":"2016","unstructured":"Perin PM, Haid S, Brown RJ et al (2016) Flunarizine prevents hepatitis C virus membrane fusion in a\u00a0genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 63:49\u201362","journal-title":"Hepatology"},{"key":"262_CR33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","volume":"509","author":"AG Khan","year":"2014","unstructured":"Khan AG, Whidby J, Miller MT et\u00a0al (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509:381\u2013384","journal-title":"Nature"},{"key":"262_CR34","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong L, Giang E, Nieusma T et\u00a0al (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342:1090\u20131094","journal-title":"Science"},{"key":"262_CR35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","volume":"501","author":"M Dorner","year":"2013","unstructured":"Dorner M, Horwitz JA, Donovan BM et\u00a0al (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501:237\u2013241","journal-title":"Nature"},{"key":"262_CR36","first-page":"577","volume":"111","author":"S Pischke","year":"2014","unstructured":"Pischke S, Behrendt P, Bock CT, Jilg W, Manns MP, Wedemeyer H (2014) Hepatitis E in Germany \u2013 an under-reported infectious disease. Dtsch Arztebl Int 111:577\u2013583","journal-title":"Dtsch Arztebl Int"},{"key":"262_CR37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","volume":"150","author":"VL Dao Thi","year":"2016","unstructured":"Dao Thi VL, Debing Y, Wu X et\u00a0al (2016) Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with Ribavirin. Gastroenterology 150:82\u201385.e4","journal-title":"Gastroenterology"},{"issue":"1","key":"262_CR38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jhep.2016.09.014","volume":"66","author":"M Valk van der","year":"2017","unstructured":"van der Valk M, Zaaijer HL, Kater AP, Schinkel J (2017) Sofosbuvir shows antiviral activity in a\u00a0patient with chronic hepatitis E virus infection. J\u00a0Hepatol 66(1):242\u2013243","journal-title":"J Hepatol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0262-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T07:51:28Z","timestamp":1569484288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0262-8"}},"subtitle":["Hepatitis\u00a0B, C, Delta und E"],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0262-8","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,19]]}}}